Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Molecularly Characterized Preclinical Platform of Subcutaneous Renal Cell Carcinoma (RCC) Patient-Derived Xenograft Models to Evaluate Novel Treatment Strategies.
Gürgen D, Becker M, Dahlmann M, Flechsig S, Schaeffeler E, Büttner FA, Schmees C, Bohnert R, Bedke J, Schwab M, Wendler JJ, Schostak M, Jandrig B, Walther W, Hoffmann J. Gürgen D, et al. Front Oncol. 2022 Jun 21;12:889789. doi: 10.3389/fonc.2022.889789. eCollection 2022. Front Oncol. 2022. PMID: 35800063 Free PMC article.
Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models.
Pusch FF, Dorado García H, Xu R, Gürgen D, Bei Y, Brückner L, Röefzaad C, von Stebut J, Bardinet V, Chamorro Gonzalez R, Eggert A, Schulte JH, Hundsdörfer P, Seifert G, Haase K, Schäfer BW, Wachtel M, Kühl AA, Ortiz MV, Wengner AM, Scheer M, Henssen AG. Pusch FF, et al. Among authors: gurgen d. Mol Cancer Ther. 2024 Apr 2;23(4):507-519. doi: 10.1158/1535-7163.MCT-23-0094. Mol Cancer Ther. 2024. PMID: 38159110 Free PMC article.
Novel signalling mechanisms and targets in renal ischaemia and reperfusion injury.
Kusch A, Hoff U, Bubalo G, Zhu Y, Fechner M, Schmidt-Ullrich R, Marko L, Müller DN, Schmidt-Ott KM, Gürgen D, Blum M, Schunck WH, Dragun D. Kusch A, et al. Among authors: gurgen d. Acta Physiol (Oxf). 2013 May;208(1):25-40. doi: 10.1111/apha.12089. Epub 2013 Mar 22. Acta Physiol (Oxf). 2013. PMID: 23432924 Review.
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma.
Dorado García H, Pusch F, Bei Y, von Stebut J, Ibáñez G, Guillan K, Imami K, Gürgen D, Rolff J, Helmsauer K, Meyer-Liesener S, Timme N, Bardinet V, Chamorro González R, MacArthur IC, Chen CY, Schulz J, Wengner AM, Furth C, Lala B, Eggert A, Seifert G, Hundsoerfer P, Kirchner M, Mertins P, Selbach M, Lissat A, Dubois F, Horst D, Schulte JH, Spuler S, You D, Dela Cruz F, Kung AL, Haase K, DiVirgilio M, Scheer M, Ortiz MV, Henssen AG. Dorado García H, et al. Among authors: gurgen d. Nat Commun. 2022 Jul 25;13(1):4297. doi: 10.1038/s41467-022-32023-7. Nat Commun. 2022. PMID: 35879366 Free PMC article.
Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.
Schmidt O, Nehls N, Prexler C, von Heyking K, Groll T, Pardon K, Garcia HD, Hensel T, Gürgen D, Henssen AG, Eggert A, Steiger K, Burdach S, Richter GHS. Schmidt O, et al. Among authors: gurgen d. J Exp Clin Cancer Res. 2021 Oct 15;40(1):322. doi: 10.1186/s13046-021-02125-z. J Exp Clin Cancer Res. 2021. PMID: 34654445 Free PMC article.
Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
Zhu Y, Blum M, Hoff U, Wesser T, Fechner M, Westphal C, Gürgen D, Catar RA, Philippe A, Wu K, Bubalo G, Rothe M, Weldon SM, Dragun D, Schunck WH. Zhu Y, et al. Among authors: gurgen d. PLoS One. 2016 Jan 4;11(1):e0145645. doi: 10.1371/journal.pone.0145645. eCollection 2016. PLoS One. 2016. PMID: 26727266 Free PMC article.
20 results